Boehringer Ingelheim Pharmaceuticals, Inc.

Mark Stephen Ralph

Abdelhakim Hammach

Daniel R Goldberg

Neil Moss

David S Thomson

Pier Francesco Cirillo

Ming-Hong Hao

Lifen Wu

Zhaoming Xiong

Donghong Amy Gao

Matthew Russell Netherton

Ronald A Aungst, Jr

Victor Marc Kamhi

Kevin Chungeng Qian

John R Regan

John Robert Proudfoot

Renee M Zindell

Daniel Kuzmich

Thomas Martin Kirrane, Jr

Christopher Ronald Sarko

Michael Jason Burke

Younes Bekkali

Pingrong Liu

Ingo Andreas Mugge

Fariba Soleymanzadeh

Joerg Bentzien

Jennifer A Kowalski

Gregory Paul Roth

Antonio J Barbosa

Thomas Wai-Ho Lee

Antonio Jose Del Moral Barbosa, Jr

Andre White

Compounds of Formula (IA) and (IB) wherein R, R, R, A, B, C, D, and E are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

Compounds of Formula (I) wherein R, R, R, R, R, R, and X are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

Disclosed are compounds of formula (I) Where Ar, X, Y, Q, W, R, R, R, Rand Rare defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. The compounds are also useful for treating diseases or conditions related to oncology and anticoagulant or fibrinolytic therapy. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Cytokine inhibitors

Disclosed are benzimidazolone compounds of formulas (I) & (II): wherein R, R, R, R, R, X, L, m, n and t are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds 

Heterocyclic compounds

Growing community of inventors

Beacon Falls, CT, United States of America

Mark Stephen Ralph